Intervention Effect of High Definition Transcranial Direct Current Stimulation (HD-tDCS) on Depressive Disorder

Depressive Disorder Clinical Trial

Official title:

Intervention Effect of High Definition Transcranial Direct Current Stimulation (HD-tDCS) on Depressive Disorder

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05286645
• Other study ID #: AHMU-tdcs-depression
• Status: Recruiting
• Phase: N/A
• Start date: January 1, 2021
• Est. completion date: December 30, 2023

Study information

• Verified date: March 2022
• Source: Anhui Medical University
• Contact: Kai Wang, PhD
• Phone: +86-0551-62923704
• Email: wangkai1964[@]126.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

To investigate the intervention effect of high definition transcranial direct current stimulation (HD-tDCS) on suicidal ideation and somatic symptoms in patients with depressive disorder and its underlying neural mechanism by MRI.

Description:

Depressive disorder is a major public health and safety problem around the world. Patients with depression often performe symptoms such as anhedonia, lack of motivation, somatic symptoms, and even suicidal ideation and behavior. The purpose of this study was to study the relieving effect of high definition transcranial direct current stimulation (HD-tDCS) on the symptoms of depression. 60 patients with depressive disorder diagnosed by DSM-5 were recruited from the fourth people's Hospital of Hefei and the first affiliated Hospital of Anhui Medical University. All participants underwent a structured interview and routine laboratory examination before and after receiving HD-tDCS. After meeting the inclusion criteria and obtaining informed consent. Each participant will complete the clinical evaluation, functional magnetic resonance imaging (fMRI) and HD-tDCS treatment conducted by trained researchers at the Neuropsychological Synergetic Innovation Center of Anhui Medical University. All the participants were randomized (1:1) to receive "active" or "sham" treatment protocol. The anode was placed over Fz with return electrodes placed at Fpz, Cz, F3 and F4. Fourteen 2-mA sessions (ramp-up and ramp-down periods of 30 and 30 seconds, respectively) were applied for 20 minutes each day over 14 consecutive sessions. Sham HD-tDCS was delivered using the same protocol and current intensity, but the period of active stimulation was only during the ramp-up and ramp-down periods of 30 and 30 seconds. Before and after the HD-tDCS treatment, the patients had receiving a battery measure of neuropsychological tests and Magnetic resonance imaging scan in multimodalities. Neuropsychological assessment included MoCA, Stroop Test, VFT, DST, AVLT, HAMD, HAMA, PHQ15, BSS(Beck scale for suicide ideation),ISI,SDS, RRS, TEPS, AES, FPQ, PVAQ and AAS. Multimodal fMRI includes 3D-T1, rs-fMRI, DTI and ASL. Neuropsychological evaluation and magnetic resonance imaging data were obtained again 24 hours after the last treatment. The symptoms of the patients were followed up one month after the end of treatment.They were instructed to focus their answers on the past week. Afterwards, they were unblinded by the study coordinator.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 60
• Est. completion date: December 30, 2023
• Est. primary completion date: December 30, 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 60 Years

Eligibility

Inclusion Criteria:

• the patients were diagnosed by more than 2 psychiatrists and met the diagnostic criteria of DSM-5 for depression, and HAMD>17, BSS>6, PHQ-15>5.
• the age ranged from 18 to 60 years old, and the length of education was more than 5 years.
• the visual acuity or corrected visual acuity is normal, right-handed, can cooperate with the completion of various experimental tests.

Exclusion Criteria:

• accompanied by severe somatic diseases, such as severe heart, liver, renal insufficiency and so on.
• accompanied by other neurological diseases, such as stroke, epilepsy and so on. pregnant and lactating women.
• accompanied by other mental disorders, such as drug abuse, schizophrenia, schizophrenic affective disorder, hysteria, autism and so on.
• patients with MRI taboos or factors affecting imaging quality, such as cardiac pacemaker, cochlear implant, cardio-cerebrovascular metal stent, metal denture, etc.
• those who could not cooperate with those who completed the relevant xperiments, such as patients with depressive stupor, claustrophobia and so on.

Related Conditions & MeSH terms

• Depression
• Depressive Disorder
• Disease
• Functional Magnetic Resonance Imaging
• Transcranial Direct Current Stimulation

Intervention

Device:
• High definition transcranial direct current stimulation
tDCS is described as a non-invasive form of brain stimulation that uses a low-intensity, constant current applied directly to the head through scalp electrodes.
• sham high definition transcranial direct current stimulation
Sham HD-tDCS was delivered using the same protocol and current intensity, but the period of active stimulation was only during the ramp-up and ramp-down periods of 30 and 30 seconds.

Locations

Country	Name	City	State
China	Anhui Medical University	Hefei

Sponsors (1)

Lead Sponsor	Collaborator
Anhui Medical University

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	change of depression symptoms of active teatment group	the change of depressive symptoms were assessed by HAMD scale.	baseline and immediately after the intervention
Primary	change of risk of suicide of active teatment group	the change of risk of suicide was assessed by Beck scale for suicide ideation.	baseline and immediately after the intervention
Primary	change of somatization symptoms of active teatment group	the change of somatization symptoms were assessed by PHQ- 15 scale.	baseline and immediately after the intervention
Primary	change of depression symptoms of sham treatment group	the change of depressive symptoms were assessed by HAMD scale.	baseline and immediately after the intervention
Primary	change of risk of suicide of sham treatment group	the change of risk of suicide was assessed by Beck scale for suicide ideation.	baseline and immediately after the intervention
Primary	change of somatization symptoms of sham treatment group	the change of somatization symptoms were assessed by PHQ- 15 scale.	baseline and immediately after the intervention
Primary	Functional MRI measures	the functional connectivity between stimulated target and the whole brain areas; the global and regional activity measures.	baseline
Primary	Functional MRI measures	the functional connectivity between stimulated target and the whole brain areas; the global and regional activity measures.	immediately after the intervention